Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study

J. M. Langley, D. M. MacDougall, B. A. Halperin, A. Swain, S. A. Halperin, K. A. Top, S. A. McNeil, D. MacKinnon-Cameron, K. Marty, G. De Serres, E. Dubé, J. A. Bettinger

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

25 Citas (Scopus)

Resumen

An outbreak of Neisseria meningitidis serotype B infection occurred at a small residential university; public health announced an organizational vaccination program with the 4-component Meningococcal B (4CMenB) vaccine (BexseroTM, Novartis/GlaxoSmithKline Inc.) several days later. Since there were limited published data on reactogenicity of 4CMenB in persons over 17 years of age, this study sought to conduct rapid surveillance of health events in vaccinees and controls using an online survey. Vaccine uptake was 84.7% for dose 1 (2967/3500) and 70% (2456/3500) for dose 2; the survey response rates were 33.0% (987/2967) and 18.7% (459/2456) in dose 1 and dose 1 recipients respectively, and 12% in unvaccinated individuals (63/533). Most students were 20–29 years of age (vaccinees, 64.0%; controls, 74.0). A new health problem or worsening of an existing health problem was reported by 30.0% and 30.3% of vaccine recipients after doses 1 and 2 respectively; and by 15.9% of controls. These health problems interfered with the ability to perform normal activities in most vaccinees reporting these events (74.7% post dose 1; 62.6% post dose 2), and in 60% of controls. The health problems led to a health care provider visit (including emergency room) in 12.8% and 14.4% of vaccinees post doses 1 and 2, respectively and in 40% of controls. The most common reactions in vaccinees were injection site reactions (20.6% post dose 1, 16.1% post dose 20 and non-specific systemic complaints (22.6% post dose 1, 17.6% post dose 2). No hospitalizations were reported. An online surveillance program during an emergency meningococcal B vaccine program was successfully implemented, and detected higher rates of health events in vaccinees compared to controls, and high rates of both vaccinees and controls seeking medical attention. The types of adverse events reported by young adult vaccinees were consistent with those previously.

Idioma originalEnglish
Páginas (desde-hasta)4046-4049
Número de páginas4
PublicaciónVaccine
Volumen34
N.º34
DOI
EstadoPublished - jul. 25 2016

Nota bibliográfica

Funding Information:
The Canadian Immunization Research Network is funded by the Public Health Agency of Canada and the Canadian Institutes of Health Research (CIHR) . JM Langley holds the CIHR-GlaxoSmithKline Chair in Pediatric Vaccinology. JAB is supported by a Career Investigator Award from the Michael Smith Foundation for Health Research .

Publisher Copyright:
© 2016 Elsevier Ltd

ASJC Scopus Subject Areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Huella

Profundice en los temas de investigación de 'Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study'. En conjunto forman una huella única.

Citar esto